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ABSTRACT: Synthesis of four iminosugars fused to a cyclopropane
ring is described using L-serine as the chiral pool. The key steps are
large-scale preparation of an α,β-unsaturated piperidinone followed by
completely stereoselective sulfur ylide cyclopropanation. Stereochemis-
try of compounds has been studied by nuclear Overhauser effect
spectroscopy (NOESY) experiments and 1H homonuclear decoupling
to measure constant couplings. The activity of these compounds against
different glycosidases has been evaluated. Although inhibition activity
was low (compound 8a presents a (Ki) of 1.18 mM against β-
galactosidase from Escherichia coli), interestingly, we found that
compounds 8a and 8b increase the activity of neuraminidase from Vibrio cholerae up to 100%.
■ INTRODUCTION
Iminosugars are azaheterocycles with promising biological
activities such as glycosidase and glycosyltransferase inhibition
and modulation.1 Many iminosugars are natural or synthetic
polyhydroxylated piperidines, which can act as biomimetics of
their corresponding pyranose analogues. Some of the most
important natural piperidine iminosugars are nojirimycin
(Figure 1, I) and its epimers, which, together with their
deoxy analogues have turned out to be the lead molecules for
drug design. Thus, stereochemical changes and functional
group variation have led to iminosugars that can modulate
glycosidase enzymes, exhibiting immunosuppressive, antiviral,
or anti-inflammatory activities.2 Bicyclic iminosugars, such as
swainsonine (II), lentiginosine (III), castanospermine (IV),
and their derivatives exhibit antitumor and immunosuppressive
activities.3
Several iminosugars, miglitol (Glyset, V),4 migalastat
(Galafold, VI),5 and miglustat (Zavesca, VII)6 are commer-
cially available for the treatment of type II diabetes and Fabry
disease, and as the first oral treatment for Gaucher disease,
respectively. Several other competitive inhibitors of glyco-
sidases are being developed as new drugs and are in different
phases of clinical trials.
The mechanism associated with glycosidase activity
modulation is generally attributed to structural similarity to
the oxacarbenium ion-like transition-state, formed during the
hydrolysis of carbohydrates.7 These transition states present
diverse conformational pathways for different glycosidases,8
making selective inhibition possible. In this context, designing
conformationally restricted inhibitors seems to be an
interesting approach. In addition, adequate metabolic stability
is needed, which may be achieved with more rigid compounds.
Recently, a study on α-mannanases showed how the enzyme
surface restricts the conformational landscape of the substrate,
rendering the B2,5 conformation the most stable on-enzyme
(Figure 2a).9 In another study, a cyclopropane containing a
cyclophellitol analogue, was designed as a specific β-
glucosidase inhibitor for enzymes reacting through the 4H3
transition-state conformation (Figure 2b).10
With these precedents, we expected that the introduction of
a three-membered ring annulated to a piperidine ring would
render novel iminosugars with a locked conformation that may
be the starting point for finding the therapeutic compounds
(Figure 3). The substituted cyclopropane moiety renders a
fixed conformation and allows many different configurations
that could increase selectivity to specific glycosidases.
The development of efficient routes for the preparation of
iminosugars has received much attention from the synthetic
community.11 Most of the methods use carbohydrates as the
chiral pool, which are transformed using reductive amina-
tions12 or other transformation strategies.13 Alternatively, some
asymmetric or biocatalysed approaches have been used.14 But,
there are fewer reports on approaches where amino acids are
used as the chiral pool for the synthesis of iminosugar
derivatives.15
Herein, we envisioned the preparation of novel bicyclic
iminosugars that include the cyclopropane motif fused with
piperidine starting from the natural amino acid L-serine as the
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chiral pool. The final compounds present five stereogenic
centers, and the synthesis involves the inversion of the
configuration of the starting L-serine (S-configuration) into
the C5 configuration of D-carbohydrates (R).16 Preliminary
glycosidase inhibition evaluation is shown.
■ RESULTS AND DISCUSSION
Our first goal was the synthesis of α,β-unsaturated ketone 5 in
which the chiral center has R configuration. This configuration
was selected as it corresponds to C5 in natural sugars and
iminosugars, which share the R configuration in that position.
This compound has already been prepared from D-serine and
described.17 In our case, we developed a synthesis approach
using cheaper and natural L-serine, as depicted in Scheme 1.
From this intermediate, a cyclopropanation reaction and
further transformations resulted in a new family of piperidines
fused to cyclopropanes. L-Serine was esterified and protected
with Boc2O, and the resulting intermediate was further
protected and reduced to give desymmetrized alcohol 1 in
which the configuration has changed from S to R in a few steps.
This compound 1 was transformed into oxazolidinone by
reaction with a base followed by allylation to give compound 2.
Following the previously reported methodology,18 2 was de-
protected and oxidized into carboxylic acid 3. This was
converted into Weinreb amide 4, which was treated with
vinylmagnesium bromide and subjected to a ring-closing
metathesis, RCM, using second-generation Grubbs’ catalyst
(Grubbs Catalyst M204), giving the starting material 5.19 This
precursor containing the piperidine core was obtained in 13%
global yield after 11 steps. No racemization was observed
during the synthesis.
The cyclopropanation reaction of 5 was performed using
sulfur ylide. Interestingly, only one reaction product was
observed and isolated in 70% yield. This product was
designated as structure 6, as a result of NMR analysis (nuclear
Figure 1. Structures of nojirimycin (I), swainsonine (II), lentiginosine (III), castanospermine (IV), miglitol (V), migalastat (VI), and miglustat
(VII).
Figure 2. Transition-state conformations on-enzyme: (a) mannose B2,5 conformation (VIII, reprinted with permission from ref 9) and (b)
cyclophellitol analogue and its 4H3 conformation (IX, ref 10, copyright 2017 American Chemical Society).
Figure 3. Structure of the target compound.
Scheme 1. Synthesis of Compound 5
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Overhauser effect (NOE) and coupling constants) of
compounds 7a−b (vide inf ra). Cyclopropanation occurred
on the same side of oxazolidinone (endo attack) and the
subsequent ring-closing step exclusively gave exo-cyclopropane.
The ylide mediated cyclopropanation is a stepwise reaction in
which the formation of the first C−C bond is the rate-
determining step.20 The attack of the ylide on 5 is more
favored from the opposite face to the nitrogen lone electron
pair as depicted in Scheme2; therefore, it occurs through the
same face of the oxazolidinone ring (endo). This selectivity
was observed previously in one unsaturated γ-lactam cyclo-
propanation,21 although other precedents have described
mixtures of endo and exo attacks.22 Then, the stereoselectivity
of cyclopropane is determined in the second step. Studies
reported by Aggarwal’s group,23 showed that two intermediate
betaines A and B are formed in a 1:1 ratio after the
nucleophilic addition. The cyclization of betaine A is faster
than that of B. Moreover, B can epimerize to give A before it
closes the three-membered ring generally leading to high
diastereoselectivity of exo-cyclopropane.
With the cyclopropane containing compound 6 in hand, the
reduction of the ketone afforded a (3:2) mixture of the two
diastereomers 7a−b (Scheme 3). These alcohols were
separated, characterized, and separately transformed into the
final products. The stereochemistry of 7a and 7b was
determined using NOE experiments and coupling constant
values. Figure 4 shows the main correlations observed for 7a
and 7b that allowed assigning the relative configuration of H6,
H7, and H7a. The coupling constants between H7a, H7, and
H6a were determined using homonuclear decoupling experi-
ments. Values are shown in Figure 4, and the model agrees
with the calculated angles for these couplings.
In continuation of the synthesis, treatment with trifluor-
oacetyl (TFA) and further reaction with ethylendiamine gave
products 8a and 8b, respectively, in excellent yields. On the
other hand, compounds 7a and 7b gave different products on
reacting with DIBAL-H, whereas 7b gave the expected alcohol
10 (62%), additionally, the reaction of 7a caused the cleavage
of the oxazolidinone ring giving 9 in 58% yield. This behavior
has been described previously (Scheme 3).25
Final compounds were screened for glycosidase inhibition
activities (α-glucosidase from Bacillus stearothermophilus, β-
glucosidase from almonds, α-galactosidase from green coffee
beans, β-galactosidase from Escherichia coli, α-mannosidase
Scheme 2. Stereoselectivity of the Cyclopropanation
Reaction of 524
Scheme 3. Synthesis of Final Compounds from 5
Figure 4. NOE signals and constant couplings in products 7a and 7b,
respectively.24
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from Jack beans, β-mannosidase from Helix pomatia, and α-L-
fucosidase from Homo sapiens) using p-nitrophenyl mono-
saccharides as substrates.
Carboxylic containing compounds 8a and 8b, could
resemble the zwitterionic form of oseltamivir and zanamivir,
well-known inhibitors of neuraminidase from Influenza virus26
with carboxyl-amino and carboxyl-guanidine moieties, respec-
tively. Preliminary docking calculations using AutoDock27
showed that 8a and 8b could fit in the binding site of
neuraminidase. Thus they were also evaluated as possible
inhibitors of neuraminidase from Vibrio cholerae.
The enzymatic activities were calculated by measuring the
absorbance of the phenoxide released in the enzymatic reaction
at 405 nm. The compounds were initially screened at 1, 5, and
25 mM concentrations. With compounds 8a and 9, inhibition
over 50% was observed with selected enzymes at 5 mM; 8b
and 10 did not show any significant inhibition of any
glycosidase (Chart 1). Inhibition constants (Ki) were
estimated assuming a competitive type inhibition in the cases
of compound 8a against β-galactosidase (Ki = 1.18 mM) and 9
against β-glucosidase (Ki = 4.43 mM). These two compounds
exhibit some selectivity such that even at 25 mM no significant
inhibition was observed against other glycosidases.
However, the observed inhibition was very weak compared
to other iminosugar-based glycosidase inhibition, for example
the measured Ki for deoxinojirimycin (DNJ) is 0.44 μM for α-
glucosidase from B. stearothermophilus. The inhibition constant
changes depending on the species that is studied, even for the
same glycosidase of other species.28 Other iminosugars present
great activity against mannosidases.29
On the other hand, we found that compounds 8a and 8b,
bearing a carboxylate group, also did not show any inhibition
against neuraminidase but unexpectedly produced activation of
the enzyme; these two compounds increased neuraminidase
activity up to 100%. The possibility that the compounds act as
favorable transglycosylation acceptors causing an increase of
nitrophenol release was considered. NMR experiments were
performed continuously following the reaction, but potential
transient transglycosylation products could not be observed.
Further research to explain this behavior is needed.
Interestingly there are not many precedents on glycosidase
activation by iminosugars. Two reports have accounted for this
activation behavior. Thus, up to 70-fold activation of some of
glycosidases was detected with multivalent iminosugars.30 In
another study, thienopyrimidines were found to activate
certain glycosidases.31 The activation mechanism could be
explained by the stabilization of the active structure of the
enzyme by the introduction of a small molecule adjacent/close
to the substrate-binding site, locking the reactive form.
Alternatively, if the activation is of the allosteric type occurring
in a site different from the active site, it could be interesting to
check if the activators have any pharmacological chaperone
activity but avoid the temporal inhibition of the enzymatic
activity, unlike the aforementioned migalastat and other
proposed pharmacological chaperones that help maintaining
the correct fold of the protein although temporally blocking
the active site of the enzyme.
■ CONCLUSIONS
We described a multigram synthesis of an α,β-unsaturated
ketone, which upon a stereoselective cyclopropanation reaction
and further transformations gave a novel series of bicyclic
piperidine-based iminosugars. The final products were studied
against different glycosidases. Inhibition in most cases was low,
but interestingly, the activation of neuraminidase was observed
with products 8. Possible explanations of this behavior, for
example, allosteric activation, enzyme stabilization, or trans-
glycosylation acceptor activity can be proposed. Current
studies in our lab will provide insight into these possible
mechanisms, and their potential applications will be explored/
pursued.
■ EXPERIMENTAL SECTION
General Information. All chemicals were obtained from
Aldrich/Merck, VWR, Fluorochem, and ABCR. Thin-layer
chromatography (TLC) analyses were performed on Merck
silica gel 60 F254 plates using phosphomolybdic acid or
anisaldehyde and heat for detection. Silica gel NORMASIL 60
40−63 μm was used for flash chromatography. NMR spectra
were recorded on a Bruker spectrometer (400 MHz for 1H and
100 MHz for 13C). Chemical shifts are reported in δ ppm
referenced to CDCl3 (δ = 7.26 for
1H and 77.00 for 13C),
CD3OD (δ = 3.31 for
1H and 49.00 for 13C), or D2O (δ = 4.79
for 1H). Bidimensional spectra (heteronuclear multiple
quantum coherence (HMQC), heteronuclear multiple bond
coherence (HMBC), correlated spectroscopy (COSY), and
nuclear Overhauser effect spectroscopy (NOESY)) were
recorded in order to carry out the assignment. IR spectra
were recorded on a Perkin-Elmer Spectrum 100. Specific
optical rotation was measured using a polarimeter Anton Parr
MCP 100. Melting points of solid compounds were
determined using a Stuart Scientific Melting Point Apparatus
SMP3. The absorbance of p-nitrophenoxide released in the
enzymatic reactions was measured at 405 nm in a Perkin-Elmer
Lamba 25.
Methyl (tert-Butoxycarbonyl)-L-serinate. Thionyl chloride
(83 mL, 1.1 mol) was added to methanol (280 mL) at 0 °C,
then L-serine (60.00 g, 571 mmol) is added. After 10 min, at 0
°C, the solution is heated at 65 °C for 2 h. The solvent is
evaporated in vacuo, and 600 mL of AcOEt and a saturated
solution of NaHCO3 (until basic pH) are added. Di-tert-butyl
dicarbonate (124.62 g, 0.571 mmol) in 265 mL of AcOEt is
added. The reaction is stirred overnight at room temperature.
Chart 1. Residual Glycosidase Activities in the Presence of 5
mM Synthesized Compounds
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c04589
ACS Omega 2020, 5, 31821−31830
31824
The aqueous layer is extracted with AcOEt (2 × 300 mL). The
combined organic layers are washed with brine (200 mL),
dried over MgSO4, and evaporated in vacuo. The crude product
is filtered through a pad of silica gel using Hex/AcOEt (9:1) to
Hex/AcOEt (3:1) as eluents. A colorless oil is obtained (101.6
g, 81% after two steps). 1H NMR (400 MHz, CDCl3) δ 5.46
(brs, 1H, NH), 4.39 (brs, 1H, CH), 3.99−3.89 (m, 2H,
CH2O), 3.78 (s, 3H, OMe), 2.47−2.32 (m, 1H, OH), 1.45 (s,
9H, 3 × CH3).
13C NMR (100 MHz, CDCl3) δ 171.6, 155.9,
80.3, 63.3, 55.8, 52.8, 28.3 (3C). IR (NaCl): 3378, 2984, 2868,
1740, 1708 cm−1. [α]D
25 (c 0.13 in dichloromethane (DCM)):
+4.14. Found: C, 49.1; H, 7.9%. Calc. for C9H17NO5: C, 49.3;
H, 7.8%.
tert-Butyl (R)-(1-((tert-Butyldimethylsilyl)oxy)-3-hydroxy-
propan-2-yl)carbamate (1). To a solution of methyl (tert-
butoxycarbonyl)-L-serinate (101.4 g, 463 mmol) in 400 mL of
dimethylformamide (DMF) cooled to 0 °C is added imidazole
(37.8 g, 555 mmol) and 4-dimethylaminopyridine (DMAP; 5.6
g, 46 mmol). After 10 min, tert-butyldimethylsilyl chloride
(73.2 g, 486 mmol) is added. The reaction is stirred for 30 min
at room temperature. AcOEt (400 mL) is added, and the
organic layer is washed with water (3 × 1 L) and brine (400
mL), dried over MgSO4, and evaporated in vacuo. To a
suspension of NaBH4 (35.0 g, 926 mmol) and LiCl (39.3 g,
926 mmol) in 800 mL of ethanol cooled to 0 °C, a solution of
the crude in 190 mL of ethanol is added slowly. The reaction is
stirred at 0 °C for 10 min, at room temperature for 30 min, and
at 50 °C for 2.5 h. The reaction is cooled to 0 °C, and a
saturated solution of NH4Cl is added (until salts are dissolved,
450 mL). The aqueous layer is extracted with AcOEt (3 × 350
mL). The combined organic layers are washed with brine (200
mL), dried over MgSO4, and evaporated in vacuo. The reaction
crude is filtered through a pad of silica gel using Hex/AcOEt
(19:1) to Hex/AcOEt (1:1) as eluents. A colorless oil is
obtained (123.2 g, 85% after two steps). 1H NMR (400 MHz,
CDCl3) δ 5.14 (brs, 1H, NH), 3.86−3.66 (m, 5H, 2 × CH2O
+ CH), 2.70 (brs, 1H, OH), 1.45 (s, 9H, 3 × CH3), 0.90 (s,
9H, 3 × CH3), 0.08 (s, 6H, 2 × CH3Si).
13C NMR (100 MHz,
CDCl3) δ 156.1, 79.6, 64.0 (2C), 52.7, 28.5 (3C), 25.9 (3C),
18.3, −5.5 (2C). IR (NaCl): 3371, 2952, 2861, 1707 cm−1.
[α]D
25 (c 0.28 in DCM): +9.30. Found: C, 55.1, H, 10.4%.
Calc. for C14H31NO4Si: C, 55.0; H, 10.2%.
(R)-4-(((tert-Butyldimethylsilyl)oxy)methyl)oxazolidin-2-
one. To a suspension of NaH 60% w/w (18.9 g, 472 mmol) in
300 mL of THF cooled to 0 °C is added a solution of 1 (123.2
g, 403 mmol) in 550 mL of THF. The reaction is stirred at 0
°C for 15 min, at room temperature for 25 min, and at 40 °C
for 2.5 h. The reaction is cooled down to 0 °C, and a saturated
solution of NH4Cl is added until all salts are dissolved (250
mL). The aqueous layer is extracted with AcOEt (2 × 500
mL). The combined organic layers are washed with brine (300
mL), dried over MgSO4, and evaporated in vacuo. A colorless
wax is obtained (78.9 g, 72%). 1H NMR (400 MHz, CDCl3) δ
6.27 (brs, 1H, NH), 4.42 (t, J = 8.6 Hz, 1H, CH2O), 4.18 (dd,
J = 8.8, 4.8 Hz, 1H, CH2O), 3.94−3.88 (m, 1H, CH), 3.60 (d,
J = 5.4 Hz, 2H, CH2OSi), 0.87 (s, 9H, 3 × CH3), 0.05 (s, 6H,
2 × CH3Si).
13C NMR (100 MHz, CDCl3) δ 160.2, 67.3, 64.8,
53.8, 25.9 (3C), 18.3, −5.4 (2C). IR (NaCl): 3315, 2959,
2848, 1745 cm−1. [α]D
25 (c 0.32 in DCM): −15.94. Found: C,
52.2, H, 9.0%. Calc. for C10H21NO3Si: C, 51.9; H, 9.2%.
(R)-3-Allyl-4-(((tert-butyldimethylsilyl)oxy)methyl)-
oxazolidin-2-one (2). To a suspension of NaH 60% w/w (16.4
g, 409.1 mmol) in 500 mL of THF at 0 °C, a solution of (R)-4-
(((tert-butyldimethylsilyl)oxy)methyl)oxazolidin-2-one (78.9
g, 340.9 mmol) in 500 mL of THF is added slowly. Allyl
bromide (29.5 mL, 340.9 mmol) is added and stirred for 15
min at 0 °C, 30 min at room temperature, and 2 h at 50 °C. A
saturated solution of NH4Cl is added until the salts are
dissolved. The aqueous layer is extracted with AcOEt (3 × 200
mL). The combined organic layers are washed with brine (150
mL) and dried over MgSO4. The solvent is evaporated in
vacuo, and the residue is filtered through a pad of silica gel
using Hex/AcOEt (19:1) to Hex/AcOEt (1:1) as eluents. A
yellow oil is obtained (64.8 g, 70%). 1H NMR (400 MHz,
CDCl3) δ 5.84−5.74 (m, 1H, HC), 5.27−5.21 (m, 2H,
H2C), 4.33 (t, J = 8.7 Hz, 1H, CH2O), 4.18−4.13 (m, 2H,
CH2O + CH2N), 3.86−3.80 (m, 1H, CH), 3.69−3.62 (m, 3H,
CH2OSi + CH2N), 0.89 (s, 9H, 3 × CH3), 0.06 (s, 6H, 2 ×
CH3Si).
13C NMR (100 MHz, CDCl3) δ 158.4, 132.7, 118.5,
65.0, 62.2, 56.0, 45.3, 25.9 (3C), 18.3, −5.4 (2C). IR (NaCl):
3084, 2948, 2866, 1744 cm−1. [α]D
25 (c 0.21 in CHCl3):
−11.84. Found: C, 57.1, H, 9.1%. Calc. for C13H25NO3Si: C,
57.5; H,9.3%.
(S)-3-Allyl-4-(hydroxymethyl)oxazolidin-2-one. To a sol-
ution of 2 (55.5 g, 204.6 mmol) in 220 mL of THF is added
TBAF·3H2O (58.8 g, 225.0 mmol). The mixture is stirred for
30 min at room temperature. The solvent is evaporated in
vacuo and filtered through a pad of silica gel using Hex/AcOEt
(2:1) to Hex/AcOEt (1:2) as eluents. A colorless oil is
obtained (28.9 g, 90%). 1H NMR (400 MHz, CDCl3) δ 5.86−
5.76 (m, 1H, HC), 5.30−5.24 (m, 2H, H2C), 4.36 (t, J =
8.8 Hz, 1H, CH2O), 4.25 (dd, J = 8.7, 6.0 Hz, 1H, CH2O),
4.09 (ddt, J = 15.7, 5.3, 1.6 Hz, 1H, CH2N), 3.90−3.84 (m,
1H, CHN), 3.80−3.73 (m, 2H, CH2N + CH2OH), 3.65 (dd, J
= 11.9, 3.3 Hz, 1H, CH2OH).
13C NMR (100 MHz, CDCl3) δ
158.7, 132.5, 118.9, 64.7, 60.9, 56.3, 45.4. IR (NaCl): 3427,
3048, 2975, 2851, 1753 cm−1. [α]D
25 (0.25 in CHCl3): −44.28.
Found: C, 53.8; H, 7.3%. Calc. for C7H11NO3: C, 53.5; H,
7.1%.
(R)-3-Allyl-2-oxo-oxazolidine-4-carboxylic Acid (3). A
solution of (S)-3-allyl-4-(hydroxymethyl)oxazolidin-2-one
(28.9 g, 184.1 mmol) in 1 L of acetone is cooled to 0 °C,
and 92 mL of Jones’ reagent is added slowly. The reaction is
stirred for 1.5 h at 0 °C. Isopropanol is added until the solution
turns blue. The mixture is filtered through a pad of celite. The
solvent is evaporated in vacuo and the residue is filtered
through a pad of silica gel using Hex/AcOEt (1:1) to AcOEt
100% as eluents. A pale yellow oil is obtained (23.0 g, 73%).
1H NMR (400 MHz, CDCl3) δ 9.83 (brs, 1H, OH), 5.80−5.70
(m, 1H, HC), 5.27−5.24 (m, 2H, H2C), 4.52 (t, J = 9.4
Hz, 1H, CH2O), 4.42 (dd, J = 9.0, 4.5 Hz, 1H, CH2O), 4.36
(dd, J = 9.7, 4.6 Hz, 1H, CHN), 4.27 (dd, J = 15.4, 4.8 Hz, 1H,
CH2N), 3.75 (dd, J = 15.4, 8.0 Hz, 1H, CH2N).
13C NMR
(100 MHz, CDCl3) δ 172.3, 158.5, 131.0, 120.1, 65.1, 56.0,
46.0. IR (NaCl): 3454, 2933, 2839, 1731 cm−1. [α]D
25 (0.30 in
CHCl3): +8.98. Found: C, 48.8; H, 5.4%. Calc. for C7H9NO4:
C, 49.1; H, 5.3%.
(R)-3-Allyl-N-methoxy-N-methyl-2-oxo-oxazolidine-4-car-
boxamide (4). A solution of 3 (23.0 g, 134.4 mmol) in 500 mL
of DCM is cooled to 0 °C. Diisopropylethylamine (DIPEA;
23.5 mL, 134.4 mmol), EDCI (25.8 g, 134.4 mmol), and N,O-
dimethylhydroxylamine hydrochloride (13.1 g, 134.4 mmol)
are added. The reaction is stirred for 2 h at 0 °C. The solvent is
evaporated in vacuo and filtered through a pad of silica gel
using Hex/AcOEt (1:4) as the eluent. A yellow oil is obtained
(25.3 g, 88%). 1H NMR (400 MHz, CDCl3) δ 5.83−5.73 (m,
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1H, HC), 5.25−5.21 (m, 2H, H2C), 4.66 (dd, J = 9.8, 5.6
Hz, 1H, CHN), 4.50 (t, J = 9.3 Hz, 1H, CH2O), 4.32 (ddt, J =
15.4, 4.7, 1.7 Hz, 1H, CH2N), 4.18 (dd, J = 8.8, 5.6 Hz, 1H,
CH2O), 3.69 (s, 3H, OCH3), 3.68 (dd, J = 15.4, 8.3 Hz, 1H,
CH2N), 3.22 (s, 3H, NCH3).
13C NMR (100 MHz, CDCl3) δ
169.6, 158.0, 132.2, 119.3, 64.5, 61.7, 54.8, 45.9, 32.7. IR
(NaCl): 3088, 2979, 2928, 1754, 1672 cm−1. [α]D
25 (c 0.37 in
DCM): +31.11. Found: C, 50.4; H, 6.9%. Calc. for
C9H14N2O4: C, 50.5; H, 6.6%.
(R)-4-Acryloyl-3-allyloxazolidin-2-one. To a solution of 4
(12.0 g, 56.0 mmol) in 270 mL of THF cooled to −30 °C, 0.7
M vinylmagnesium bromide (200 mL) is added slowly,
keeping the temperature below −25 °C. When the addition
is finished, the reaction is stirred for another 30 min at −30 °C.
The reaction mixture is poured into a mixture of 200 mL of
HCl 10% and 100 mL of MeOH cooled in a bath at −15 °C.
This mixture is stirred for another 15 min. The aqueous layer is
extracted with AcOEt (3 × 150 mL). The combined organic
layers are washed with a solution of 1 M HCl (200 mL), with a
saturated solution of NaHCO3 (150 mL) and brine (150 mL),
dried over MgSO4, and evaporated in vacuo. The crude is used
without further purification. 1H NMR (400 MHz, CDCl3) δ
6.50 (dd, J = 17.5, 10.4 Hz, 1H, CHCO), 6.39 (d, J = 17.4
Hz, 1H, H2C CHCO, trans), 6.01 (d, J = 10.4 Hz, 1H, H2C CHCO, cis), 5.78−5.68 (m, 1H, HC), 5.24−5.16 (m,
2H, H2C), 4.59 (dd, J = 10.0, 5.2 Hz, 1H, CHN), 4.52 (t, J
= 9.3 Hz, 1H, CH2O), 4.26 (dd, J = 15.3, 4.6 Hz, 1H, CH2N),
4.15 (dd, J = 8.6, 5.2 Hz, 1H, CH2O), 3.59 (dd, J = 15.3, 8.0
Hz, 1H, CH2N).
13C NMR (100 MHz, CDCl3) δ 195.1, 157.7,
132.3, 131.8, 131.4, 120.1, 63.8, 60.5, 46.2.
(R)-1,8a-Dihydro-3H-oxazolo[3,4-a]pyridine-3,8(5H)-
dione (5). The crude of the previous reaction is dissolved in
180 mL of DCM and heated to reflux. Grubb’s second-
generation catalyst is added (1.2 g, 1.4 mmol). The reaction is
stirred under reflux for 1.5 h. The solvent is evaporated in
vacuo. The crude is purified in silica gel in Hex/AcOEt (1:1). A
brown oil is obtained (5.6 g, 65% after two steps). 1H NMR
(400 MHz, CDCl3) δ 7.06 (ddd, J = 10.5, 4.4, 2.0 Hz, 1H, 
CHCH2), 6.26 (dt, J = 10.5, 2.3 Hz, 1H, CHCO), 4.69 (dd,
J = 9.0, 4.4 Hz, 1H, CHN), 4.61−4.50 (m, 2H, CH2O +
CH2N), 4.27 (ddd, J = 9.4, 4.4, 2.1 Hz, 1H, CH2O), 4.02 (dq, J
= 20.5, 2.3 Hz, 1H, CH2N).
13C NMR (100 MHz, CDCl3) δ
192.1, 157.4, 146.5, 127.7, 64.2, 57.9, 41.8. IR (NaCl): 3081,
2959, 2920, 2854, 1752, 1748 cm−1. [α]D
25 (c 0.09 in DCM):




a solution of 5 (2.4 g, 15.9 mmol) in 13 mL of DCM at 0 °C is
added a solution of tert-butyl (tetrahydrothiophenylidene)-
acetate (9.6 g, 47.6 mmol) in 207 mL of DCM slowly. The
reaction is stirred at room temperature for 30 min. Deionized
water (20 mL) is added. The aqueous layer is extracted with
DCM (2 × 30 mL). The combined organic phases are washed
with brine (20 mL), dried over MgSO4, and evaporated in
vacuo. The crude is purified in silica gel using Hex/AcOEt
(2:1) as the eluent. A yellow wax is obtained (3.0 g, 70%). 1H
NMR (400 MHz, CDCl3) δ 4.53 (t, J = 9.7 Hz, 1H, CH2O),
4.32 (dd, J = 9.3, 5.7 Hz, 1H, CH2O), 4.23 (d, J = 14.1 Hz, 1H,
CH2N), 4.04 (dd, J = 10.3, 5.7 Hz, 1H, CHN), 3.53 (d, J =
14.0 Hz, 1H, CH2N), 2.39 (dd, J = 7.9, 4.2 Hz, 1H, CHCO),
2.21−2.18 (m, 1H, CHCH2N) 2.10 (t, J = 4.5 Hz, 1H,
CHCO2), 1.44 (s, 9H, 3 × CH3).
13C NMR (100 MHz,
CDCl3) δ 200.0, 168.9, 156.9, 82.8, 64.2, 58.8, 37.2, 31.6, 28.1,
24.5, 22.7. IR (NaCl): 2975, 2863, 1748, 1736, 1719 cm−1.
[α]D
25 (c 0.11 in DCM): +38.02. Found: C, 58.0; H, 4.9%.
Calc. for C13H17NO5: C, 58.4; H, 4.6%.
tert-Butyl (5aR,6S,6aS,7S,7aR) and tert-butyl (5aR,6-
S ,6aS,7R,7aR)-7-Hydroxy-3-oxohexahydro-1H,3H-
cyclopropa[d]oxazolo[3,4-a]pyridine-6-carboxylate (7a and
7b). To a solution of 6 (1.1 g, 4.1 mmol) in 35 mL of absolute
ethanol at 0 °C is added NaBH4 (312 mg, 8.2 mmol). The
reaction is stirred for 1 h at room temperature. A solution of
saturated NH4Cl (20 mL) and water (until salts dissolve) is
added. The aqueous phase is extracted with AcOEt (3 × 60
mL). The combined organic layers are washed with brine (50
mL), dried over MgSO4, and evaporated in vacuo. The crude
contained a 3:2 mixture of isomers 7a/7b as determined by the
integration of signals in the 1H NMR spectrum of the reaction
crude. This mixture was separated by silica gel chromatography
using Hex/AcOEt (1:1) to Hex/AcOEt (1:2) as eluents. A
yellow wax is obtained for isomer 7a (463 mg, 42%). A yellow
solid is obtained for isomer 7b (330 mg, 30%).
Spectroscopic data for tert-butyl (5aR,6S,6aS,7S,7aR)-7-
hydroxy-3-oxohexahydro-1H,3H-cyclopropa[d]oxazolo[3,4-a]-
pyridine-6-carboxylate 7a: 1H NMR (400 MHz, CDCl3) δ 4.52
(t, J = 8.6 Hz, 1H, CH2O), 4.12 (dd, J = 9.1, 4.8 Hz, 1H,
CH2O), 4.00 (d, J = 13.6 Hz, 1H, CH2N), 3.80 (dd, J = 8.5,
4.5 Hz, 1H, CHOH), 3.40 (dd, J = 13.6, 4.1 Hz, 1H, CH2N),
3.33 (td, J = 8.3, 4.9 Hz, 1H, CHN), 2.41 (d, J = 5.0 Hz, 1H,
OH), 1.76−1.70 (m, 1H, CHCH2N), 1.67 (dd, J = 9.1, 5.0 Hz,
1H, CHCHOH), 1.44 (s, 9H, 3 × CH3), 1.40 (t, J = 4.9 Hz,
1H, CHCO2).
13C NMR (100 MHz, CDCl3) δ 172.2, 157.5,
81.4, 69.0, 68.3, 56.8, 38.5, 28.2 (3C), 27.3, 24.5, 20.3. IR
(NaCl): 3361, 2975, 2863, 1748, 1736 cm−1. [α]D
25 (c 0.14 in
DCM): −2.20. Found: C, 58.2; H, 6.8%. Calc. for C13H19NO5:
C, 58.0; H, 7.1%.
Spectroscopic data for tert-butyl (5aR,6S,6aS,7R,7aR)-7-
hydroxy-3-oxohexahydro-1H,3H-cyclopropa[d]oxazolo[3,4-a]-
pyridine-6-carboxylate 7b: 1H NMR (400 MHz, CDCl3) δ
4.54 (dd, J 0 8.5, 6.4 Hz, 1H, CH2O), 4.29 (t, J = 8.8 Hz, 1H,
CH2O), 4.24−4.20 (m, 1H, CHOH), 4.00 (d, J = 13.4 Hz, 1H,
CH2N), 3.61−3.55 (m, 1H, CHN), 3.29 (dd, J = 13.4, 4.0 Hz,
1H, CH2N), 2.11 (td, J = 8.4, 5.0 Hz, 1H, CHCHOH), 1.97
(d, J = 4.1 Hz, 1H, OH), 1.84−1.74 (m, 2H, 2 × CH
cyclopropane), 1.44 (s, 9H, 3 × CH3).
13C NMR (100 MHz,
CDCl3) δ 172.1, 157.8, 81.5, 63.1, 60.4, 55.7, 38.8, 28.3 (3C),
25.9, 21.2, 20.5. IR (KBr): 3361, 2975, 2863, 1748, 1736 cm−1.
[α]D
25 (c 0.04 in DCM): −10.46. Found: C, 58.3; H, 7.0%.
Calc. for C13H19NO5: C, 58.0; H, 7.1%. Mp > 180.0 °C, dec.
(5aR,6S,6aS,7S,7aR)-7-Hydroxy-3-oxohexahydro-1H,3H-
cyclopropa[d]oxazolo[3,4-a]pyridine-6-carboxylic Acid. To a
solution of 7a (250 mg, 0.9 mmol) in 1.5 mL of DCM is added
9.3 mL of TFA at room temperature. The reaction is stirred for
30 min. The solvent is evaporated in vacuo. Toluene is added
until all TFA is evaporated. The crude is purified in silica gel in
10% DCM/MeOH. A brown wax is obtained (187 mg, 94%).
1H NMR (400 MHz, MeOD) δ 4.54 (t, J = 8.5 Hz, 1H,
CH2O), 4.14 (dd, J = 8.9, 5.2 Hz, 1H, CH2O), 3.87 (d, J =
13.6 Hz, 1H, CH2N), 3.82 (d, J = 8.7 Hz, 1H, CHOH), 3.44
(dd, J = 13.5, 4.2 Hz, 1H, CH2N), 3.37 (td, J = 8.5, 5.2 Hz, 1H,
CHN), 1.84−1.75 (m, 1H, CHCH2N), 1.70 (dd, J = 9.3, 4.7
Hz, 1H, CHCHOH), 1.38 (brs, 1H, CHCO2).
13C NMR (100
MHz, D2O) δ 176.6, 159.5, 69.8, 69.6, 58.2, 39.5, 29.0, 24.5,
21.9. IR (NaCl): 3396, 2984, 2851, 1748, 1729 cm−1. [α]D
25 (c
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0.05 in MeOH): −3.68. Found: C, 51.1; H, 5.3%. Calc. for
C9H11NO5: C, 50.7; H, 5.2%.
(5aR,6S,6aS,7R,7aR)-7-Hydroxy-3-oxohexahydro-1H,3H-
cyclopropa[d]oxazolo[3,4-a]pyridine-6-carboxylic Acid. To a
solution of 7b (86 mg, 0.3 mmol) in 1 mL of DCM is added
3.2 mL of TFA at room temperature. The reaction is stirred for
30 min. The solvent is evaporated in vacuo. Toluene is added
until all TFA is evaporated. The crude is purified in silica gel in
10% DCM/MeOH. A brown wax is obtained (60 mg, 90%).
1H NMR (400 MHz, D2O) δ 4.47 (dd, J = 8.5, 5.8 Hz, 1H,
CH2O), 4.31 (t, J = 8.8 Hz, 1H, CH2O), 4.17 (dd, J = 8.0, 3.8
Hz, 1H, CHOH), 3.86 (d, J = 13.4 Hz, 1H, CH2N), 3.71 (ddd,
J = 9.5, 5.9, 3.9 Hz, 1H, CHN), 3.38 (dd, J = 13.4, 4.4 Hz, 1H,
CH2N), 2.09 (td, J = 8.4, 4.7 Hz, 1H, CHCHOH), 1.82 (t, J =
4.9 Hz, 1H, CHCO2), 1.80−1.75 (m, 1H, CHCH2N). 13C
NMR (100 MHz, D2O) δ: 177.7, 159.6, 64.2, 59.8, 55.4, 38.4,
26.0, 21.2, 20.0. IR (KBr): 3388, 2991, 2867, 1740, 1732 cm−1.
[α]D
25 (c 0.02 in MeOH): −48.87. Found: C, 51.0; H, 4.9%.
Calc. for C9H11NO5: C, 50.7; H, 5.2%. Mp > 205.4 °C, dec.
(1R,4R,5S,6S,7S)-5-Hydroxy-4-(hydroxymethyl)-3-
azabicyclo[4.1.0]heptane-7-carboxylic Acid (8a). To a
solution of (5aR,6S,6aS,7S,7aR)-7-hydroxy-3-oxohexahydro-
1H,3H-cyclopropa[d]oxazolo[3,4-a]pyridine-6-carboxylic acid
(187 mg, 0.9 mmol) in 2 mL of MeOH is added
ethylenediamine (0.18 mL, 2.6 mmol) at room temperature
and heated at 60 °C for 1.5 h. The solvent is evaporated in
vacuo and methanol is added to evaporate excess amine. A
solution of HCl 4 N in dioxane (5 mL) is added and stirred for
30 min. A yellow wax is obtained (150 mg, 91%).1H NMR
(400 MHz, MeOD) δ 4.54 (t, J = 8.5 Hz, 1H, CH2O), 4.14
(dd, J = 8.9, 5.3 Hz, 1H, CH2O), 3.86 (d, J = 13.5 Hz, 1H,
CH2N), 3.72 (d, J = 8.7 Hz, 1H, CHOH), 3.44 (dd, J = 13.5,
4.3 Hz, 1H, CH2N), 3.36 (td, J = 8.4, 5.2 Hz, 1H, CHN),
1.78−1.70 (m, 1H, CHCH2N), 1.67 (dd, J = 9.2, 4.9 Hz, 1H,
CHCHOH), 1.32 (t, J = 4.9 Hz, 1H, CHCO2).
13C NMR (100
MHz, MeOD) δ 159.5, 70.1, 69.6, 58.2, 39.6, 28.5, 25.7, 21.3.
IR (NaCl): 3405, 2996, 2895, 1736 cm−1. [α]D
25 (c 0.05 in
MeOH): −5.41. Found: C, 51.0; H, 7.2%. Calc. for
C8H13NO4: C, 51.3; H, 7.0%.
(1R,4R,5R,6S,7S)-5-Hydroxy-4-(hydroxymethyl)-3-azabicy-
clo [4.1.0]heptane-7-carboxylic Acid (8b). To a solution of
(5aR,6S,6aS,7R,7aR)-7-hydroxy-3-oxohexahydro-1H,3H-
cyclopropa[d]oxazolo[3,4-a]pyridine-6-carboxylic acid (75 mg,
0.4 mmol) in 1 mL of MeOH is added ethylenediamine (0.07
mL, 1.1 mmol) and heated at 60 °C for 1.5 h. The solvent is
evaporated in vacuo and methanol is added to evaporate excess
amine. A solution of HCl 4 N in dioxane (1 mL) is added and
stirred for 30 min. A yellow wax is obtained (60 mg, 90%). 1H
NMR (400 MHz, MeOD) δ 4.47 (dd, J = 8.5, 6.0 Hz, 1H,
CH2O), 4.30 (t, J = 8.8 Hz, 1H, CH2O), 4.16 (dd, J = 8.0, 3.9
Hz, 1H, CHOH), 3.84 (d, J = 13.3 Hz, 1H, CH2N), 3.75−3.62
(m, 1H, CHN), 3.37 (dd, J = 13.2, 4.4 Hz, 1H, CH2N), 2.11−
1.93 (m, 1H, CHCHOH), 1.79−1.64 (m, 2H, 2 × CH
cyclopropane). 13C NMR (100 MHz, MeOD) δ 158.80, 63.53,
59.64, 55.65, 38.46, 25.01, 21.50, 19.60. IR (NaCl): 3402,
2984, 2890, 1733 cm−1. [α]D
25 (c 0.02 in MeOH): −32.0.
Found: C, 51.4; H, 7.2%. Calc. for C8H13NO4: C, 51.3; H,
7.0%.
(1S,4R,5S,6S,7S)-4,7-bis(Hydroxymethyl)-3-methyl-3-
azabicyclo[4.1.0]heptan-5-ol (9). To a solution of 7a (120
mg, 0.5 mmol) in 3 mL of DCM is added 1.86 mL of DIBAL-
H 1,2M in toluene at 0 °C. The reaction is stirred for 4 h at
room temperature. Methanol is added (10 mL). The salts are
filtered and rinsed with methanol (2 × 10 mL). The solvent is
evaporated in vacuo. The crude is purified in silica gel using
MeCN/H2O (9:1) as the eluent. A yellow wax is obtained (49
mg, 58%). 1H NMR (400 MHz, MeOD) δ 3.81 (dd, J = 11.7,
3.2 Hz, 1H, CH2O), 3.77−3.71 (m, 2H, CH2O + CHOH),
3.45 (dd, J = 11.3, 6.7 Hz, 1H; HOCH2Ccyclopropane), 3.37
(dd, J = 11.3, 6.8 Hz, 1H, HOCH2Ccyclopropane), 3.07 (d, J =
11.7 Hz, 1H, CH2N), 2.63 (dd, J = 11.6, 3.9 Hz, 1H, CH2N),
2.38 (s, 3H, NCH3), 1.75 (dt, J = 7.9, 2.9 Hz, 1H, CHN),
1.23−1.15 (m, 1H, HOCH2CHcyclopropane), 1.12−1.03 (m,
1H, CHCH2N), 0.99 (dd, J = 9.0, 4.6 Hz, 1H, CHCHOH).
13C NMR (100 MHz, MeOD) δ 70.2, 67.1, 65.9, 60.1, 55.6,
43.0, 23.24, 23.22, 17.3. IR (NaCl): 3357, 2993, 2892 cm−1.
[α]D
25 (c 0.03 in MeOH): −4.65. Found: C, 57.5, H, 9.5%.
Calc. for C9H17NO3: C, 57.7; H, 9.2%.
(5aS,6S,6aS,7R,7aR)-7-Hydroxy-6-(hydroxymethyl)-
hexahydro-1H,3H-cyclopropa[d]oxazolo[3,4-a]pyridin-3-
one (10). To a solution of 7b (117 mg, 0.4 mmol) in 3 mL of
DCM at 0 °C is added 1.80 mL of 1,2M DIBAL-H in toluene.
The reaction is stirred for 4 h at room temperature. Methanol
is added (10 mL). The salts are filtered and rinsed with
methanol (2 × 10 mL). The solvent is evaporated in vacuo.
The crude is purified in silica gel using MeCN as the eluent. A
yellow wax is obtained (54 mg, 62%). 1H NMR (400 MHz,
MeOD) δ 4.48 (dd, J = 8.5, 5.8 Hz, 1H, CH2O), 4.32 (t, J =
8.8 Hz, 1H, CH2O), 4.16 (dd, J = 8.1, 3.8 Hz, 1H, CHOH),
3.83 (d, J = 12.9 Hz, 1H, CH2N), 3.69 (ddd, J = 9.4, 5.8, 3.8
Hz, 1H, CHN), 3.54 (dd, J = 11.2, 6.4 Hz, 1H,
HOCH2Ccyclopropane), 3.42 (dd, J = 11.3, 6.7 Hz, 1H,
HOCH2Ccyclopropane), 3.36 (dd, 12.9, 4.7 Hz, 1H, CH2N),
1.42 (td, J = 8.4, 4.9 Hz, 1H, CHCHOH), 1.30−1.20 (m, 1H,
HOCH2CH cyclopropane), 1.19−1.09 (m, 1H, CHCH2N).
13C NMR (100 MHz, MeOD) δ 160.4, 65.6, 65.0, 61.4, 57.2,
40.2, 21.9, 21.0, 16.5. IR (NaCl): 3384, 2991, 2888, 1705
cm−1. [α]D
25 (c 0.01 in MeOH): −35.3. Found: C, 54.5; H,
6.5%. Calc. for C9H13NO4: C, 54.3; H, 6.6%.
General Procedure for Enzymatic Reactions. Glyco-
sidase activities were assessed in 80 μL reaction volumes in
Eppendorf vials. Buffer composition and enzyme concentration
were adjusted depending on the enzyme assayed: 20 mM
Na2HPO4 at pH 7.3 for β-glucosidase (3 μg/mL) and β-
galactosidase (1 μg/mL); 20 mM Na2HPO4 at pH 6.8 for α-
glucosidase (1 μg/mL) and α-galactosidase (20 μM); 20 mM
NaH2PO4 at pH 5.5 for α- and β-mannosidase (7 and 2 μM
respectively); 0.1 M NaOAc at pH 4.0 with 1 mg/mL of
bovine serum albumin (BSA) for α-L-fucosidase (2 μM); and
50 mM NaOAc at pH 5.0 for neuraminidase (6 μM). The
inhibitors were tested at 1, 5, and 25 mM final concentrations
in the assays. Each enzyme mixture and inhibitor were
homogenized and preincubated for 10 min at 37 or 40 °C
(α-L-fucosidase). Each reaction was initiated and brought to a
final volume of 80 μL, by addition of an aliquot of the
corresponding p-nitrophenyl glycoside substrate to obtain the
following final concentrations in the reaction mixtures: p-
nitrophenyl α- and β-D-glucopyranoside (1 mM), p-nitro-
phenyl α- and β-D-galactopyranoside (0.5 mM), p-nitrophenyl
α- and β-D-mannopyranoside (1 mM), p-nitrophenyl α-L-
fucopyranoside (1 mM), or p-nitrophenyl neuraminic acid (1
mM). After 10 min of incubation time at the same
temperature, each reaction was quenched with 400 μL of 1.0
M Na2CO3, and the absorbance at 405 nm was measured.
Assays were repeated twice and data were averaged.
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The residual activity of each enzyme was calculated by the
ratio of the absorbance measured after 10 min of reaction in
the presence and absence of synthesized compounds. The
equation used to calculate Ki was derived from Michaelis−
Menten, where Vi is the absorbance measured in the absence of
the synthesized compounds; V is the absorbance when the
compounds were added to the enzymatic reaction; Km
indicates the Michaelis−Menten constant for each enzyme;
and [I] is the concentration of the synthesized compounds (5
mM) and [S] is the concentration of the substrate (eq 1).
Calculated Ki for compounds 8a and 9
K
K I
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(18) Moisan, L.; Thueŕy, P.; Nicolas, M.; Doris, E.; Rousseau, B.
Formal synthesis of (+)-Catharanthine. Angew. Chem., Int. Ed. 2006,
45, 5334−5336.
(19) For a review on RCM reaction for the synthesis of iminosugars,
see: Dragutan, I.; Dragutan, V.; Demonceau, A. Targeted drugs by
olefin metathesis: piperidine-based iminosugars. RSC Adv. 2012, 2,
719−736.
(20) (a) Appel, R.; Hartman, N.; Mayr, H. Scope and limitations of
cyclopropanations with sulphur ylides. J. Am. Chem. Soc. 2010, 132,
17894−17900. (b) Appel, R.; Mayr, H. Nucleophilic reactivities of
sulphur ylides and related carbanions: comparison with structurally
related organophosphorous compounds. Chem. - Eur. J. 2010, 16,
8610−8614. For the synthesis of ylide see: (c) Henry, S. S.; Brady,
M. D.; laird, D. L. T.; Ruble, J. C.; Varie, D. L.; Monn, J. A. Improved
synthesis of C4α- and C4β-Methyl analogues of 2-Aminobicyclo
[3.1.0] hexane -2,6-dicarboxylate. Org. Lett. 2012, 14, 2662−2665.
(21) Romo, D.; Meyers, A. I. An asymmetric route to enantiomeri-
cally pure 1,2,3-trisubstituted cyclopropanes. J. Org. Chem. 1992, 57,
6265−6270.
(22) Zhang, R.; Mamai, A.; Madalengoitia, J. S. Cyclopropanation
Reactions of Pyroglutamic Acid-Derived Synthons with Akylidene
Transfer Reagents. J. Org. Chem. 1999, 64, 547−555.
(23) (a) Riches, S. L.; Saha, C.; Filgueira, N. F.; Grange, E.;
McGarrigle, E. M.; Aggarwal, V. K. On the mechanism of ylide-
mediated cyclopropanations: evidence for a proton-transfer step and
its effects on stereoselectivity. J. Am. Chem. Soc. 2010, 132, 7626−
7630. (b) Aggarwal, V. K.; Grange, E. Asymmetric sulfonium ylide
mediated cyclopropanation: stereocontrolled synthesis of
(+)-LY354740. Chem. - Eur. J. 2006, 12, 568−575.
(24) Modelling was done using Chimera 1.13.1, charges were
computed using ANTECHAMBER: Wang, J.; Wang, W.; Kollman, P.
A.; Case, D. A. Automatic atom type and bond perception in
molecular mechanical calculations. J. Mol. Graphics Modell. 2006, 25,
247−260.
(25) Gonda, T.; Balaźs, A.; Tot́h, G.; Fülöp, F.; Szakonyi, Z.
Stereoselective synthesis and transformations of pinane-based 1,3-
diaminoalcohols. Tetrahedron 2017, 73, 2638−2648.
(26) (a) Russell, R. J.; Haire, L. F.; Stevens, D. J.; Collins, P. J.; Lin,
Y. P.; Blackburn, G. M.; Hay, A. J.; Gambling, S. J.; Skehel, J. J. The
structure of H5N1 avian influenza neuraminidase suggest new
opportunities for drug design. Nature 2006, 443, 45−49. (b) Lew,
W.; Chen, X.; Kim, C. U. Discovery and development of GS 4104
(oseltamivir): an orally active influenza neuraminidase inhibitor. Curr.
Med. Chem. 2000, 7, 663−672.
(27) PDB file of N8 Neuraminidase from Inf luenza virus in complex
with oseltamivir (2HT8) was obtained from Protein data Bank.
Ligands were first minimized as ref 22. Docking was calculated using
Lamarckian Genetic Algorithm parameters.
(28) Zamoner, L. O. B.; Aragao-Leoneti, V.; Carvalho, I.
Iminosugars: effects of stereochemistry, ring size and N-substituents
on glucosidase activities. Pharmaceuticals 2019, 12, No. 108.
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